AU2092300A - Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders - Google Patents

Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders

Info

Publication number
AU2092300A
AU2092300A AU20923/00A AU2092300A AU2092300A AU 2092300 A AU2092300 A AU 2092300A AU 20923/00 A AU20923/00 A AU 20923/00A AU 2092300 A AU2092300 A AU 2092300A AU 2092300 A AU2092300 A AU 2092300A
Authority
AU
Australia
Prior art keywords
gonadien
diones
estrogens
prophylaxis
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20923/00A
Inventor
Rene De Beun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2092300A publication Critical patent/AU2092300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU20923/00A 1999-01-18 2000-01-17 Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders Abandoned AU2092300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900050 1999-01-18
DKPA199900050 1999-01-18
PCT/DK2000/000020 WO2000041700A1 (en) 1999-01-18 2000-01-17 Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders

Publications (1)

Publication Number Publication Date
AU2092300A true AU2092300A (en) 2000-08-01

Family

ID=8089168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20923/00A Abandoned AU2092300A (en) 1999-01-18 2000-01-17 Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders

Country Status (2)

Country Link
AU (1) AU2092300A (en)
WO (1) WO2000041700A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
WO2002069975A1 (en) * 2001-03-02 2002-09-12 Stem Cell Therapeutics Inc. Use of estrogen to induce neural stem cell increase
WO2002069976A2 (en) * 2001-03-02 2002-09-12 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200404551A (en) * 2002-05-17 2004-04-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3888597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
WO2000041700A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
EP1143956A3 (en) Compositions and methods for the treatment of anorectal disorders
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU3725997A (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU2009201956A2 (en) Pregnane steroids for use in the treatment of CNS disorders
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
AU4171500A (en) Flupirtine in the treatment of fibromyalgia and related conditions
AUPQ246799A0 (en) Surgical screw and guidewire
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
AU6910600A (en) Methods for the treatment of mental disorders
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2002247876A1 (en) Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
AU5240700A (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
AU2092300A (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
AU5006499A (en) Compositions and methods for the treatment or prevention of pulmonary infections
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU2663300A (en) Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase